Review

Diversity Considerations in HIV-1 Vaccine Selection

Science  28 Jun 2002:
Vol. 296, Issue 5577, pp. 2354-2360
DOI: 10.1126/science.1070441

You are currently viewing the abstract.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


Abstract

Globally, human immunodeficiency virus–type 1 (HIV-1) is extraordinarily variable, and this diversity poses a major obstacle to AIDS vaccine development. Currently, candidate vaccines are derived from isolates, with the hope that they will be sufficiently cross-reactive to protect against circulating viruses. This may be overly optimistic, however, given that HIV-1 envelope proteins can differ in more than 30% of their amino acids. To contend with the diversity, country-specific vaccines are being considered, but evolutionary relationships may be more useful than regional considerations. Consensus or ancestor sequences could be used in vaccine design to minimize the genetic differences between vaccine strains and contemporary isolates, effectively reducing the extent of diversity by half.

  • * To whom correspondence should be addressed. E-mail: btk{at}t10.lanl.gov

View Full Text

Cited By...